Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN04 first-in-human open-label dose-escalation and expansion study in solid tumors
NL-OMON50396Phase 2Active, not recruiting
- Sponsor
- Cantargia AB
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nadunolimab in non-small cell lung cancer (NSCLC), pancreatic adenocarcinoma (PDAC), triple-negative breast cancer (TNBC), colorectal cancer (CRC), Non-hematologic malignancy, sponsored by Cantargia AB. Started Dec 2017; status: active, not recruiting.
02
Drugs
nadunolimab
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic adenocarcinoma (PDAC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON50396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50396.